The molecular genetic research on panic disorder (PD) has grown tremendously in the past decade. Although the data from twin and family studies suggest an involvement of genetic factors in the familial transmission of PD with the heritability estimate near 40%, the genetic substrate underlying panicogenesis is not yet understood. The linkage studies so far have suggested that chromosomal regions 13q, 14q, 22q, 4q31-q34, and probably 9q31 are associated with the transmission of PD phenotypes. To date, more than 350 candidate genes have been examined in association studies of PD, but most of these results remain inconsistent, negative, or not clearly replicated. Only Val158Met polymorphism of the catechol-O-methyltransferase gene has been implicated in susceptibility to PD by several studies in independent samples and confirmed in a recent meta-analysis. However, the specific role of this genetic variation in PD requires additional analysis considering its genderand ethnicity-dependent effect and putative impact on cognitive functions. The recent advantages in bioinformatics and genotyping technologies, including genome-wide association and gene expression methods, provide the means for far more comprehensive discovery in PD. The progress in clinical and neurobiological concepts of PD may further guide genetic research through the current controversies to more definitive findings.
Introduction
Panic disorder (PD) is a serious and potentially disabling psychiatric condition characterized by unexpected panic attacks and fear of their recurrence or harmful consequences, with the frequent development of agoraphobia. 1 The core phenomena of PD are spontaneous panic attacks defined by the rapidly escalating occurrence of multiple physical and psychological symptoms of intense distress. Epidemiological surveys have shown lifetime prevalence of PD with or without agoraphobia at 4.8% with female preponderance, typically young adult age of onset and major functional impairment. 2, 3 PD is highly comorbid with other anxiety disorders, such as social anxiety disorder, generalized anxiety disorder (GAD), major depressive disorder (MDD), and substance use disorders. A portion of this comorbidity is likely due to phenotypic overlap within the internalizing disorder spectrum as well as shared genetic and nongenetic risk factors. 4 Furthermore, the pathogenesis of PD is complex, likely involving psychological, biological, and survival-related evolutionary factors and their interactions. Several cognitive theories and psychobiological models have been proposed to explain the onset and development of PD, [5] [6] [7] but the neurobiological mechanisms and substrates of panic attacks and PD are not clearly understood. The most comprehensive neuroanatomical model of PD has suggested an abnormal sensitivity in the brain mechanisms of fear and alarm response involving a network of neuronal pathways and multiple neurotransmitter systems, including serotonin (5-hydroxytryptamine, 5-HT), norepinephrine, gamma-aminobutyric acid (GABA), and others. Accordingly, panic attacks originate from a dysfunction in the brain fear network that integrates various structures of the brainstem, the amygdala, the hypothalamus, and the cortical regions. Thus, antipanic medications and psychotherapy may act at different neuroanatomical levels normalizing various aspects of fear network underlying the manifestations of PD. 8 The data from twin and family studies suggest a substantial involvement of genetic factors in the familial transmission of PD, with heritability estimated near 40%. 9 The key approaches aiming to clarify the sources of genetic risk have been linkage and association analyses. Linkage studies provide an approximate chromosomal location of the gene(s) associated with a familial transmission of target phenotypes. These studies use the logarithm of the odds (LOD) to estimate the likelihood of two genetic loci (genotyped markers and disease loci) to be inherited together. Several multi-family, genomewide linkage analyses of PD, including some studies of a broader panic-related phenotype, have been published (summarized by Middeldorp et al., 10 Smoller et al.
11
). Linkage analysis has the advantage of being an unbiased, comprehensive search across the genome for susceptibility genes and alleles; however, it is limited by weak power to detect and localize the effect of common alleles with modest effects. More recent efforts focus on candidate genes, in which current knowledge of the pathophysiology of anxiety and the mode of action of drugs and challenge agents, along with the findings in other psychiatric disorders, are used to make sensible choice of specific genes for testing. This approach aims to link the illness to common variations in DNA sequence, such as sequence repeats or single nucleotide polymorphisms (SNP) and patterns of their proximate occurrence (haplotypes). These studies commonly use an association paradigm with casecontrol design and/or family-based analyses and have stronger power to identify loci influencing complex traits than linkage studies.
To date more than 350 candidate genes including more than 1000 polymorphisms have been analyzed for their association with PD (Supplementary  Table 1 ). Despite these extensive efforts, most studies have produced results that are inconsistent, negative, or not clearly replicated, 12 indicating that the genetic basis of PD, like that of other common psychiatric conditions, requires further elucidation. A smaller proportion of reports have indicated possible associations of PD phenotypes with certain polymorphisms. Earlier studies have predominantly focused on classic candidate genes, the 'usual suspects,' or on those putatively relevant to PD pathogenesis, such as genes related to 5-HT, cholecystokinin (CCK), dopamine, or adenosine systems. More recent molecular research has extended the search to candidate genes related to hormonal, opioid, immune, neurotrophic, and other systems. Overall, these studies suggest that most of the studied candidates are not likely to have a major role in the susceptibility to PD.
In this paper, we review the extant literature on molecular genetics of PD, addressing the promises and caveats of these studies, and highlight the trends and perspectives in this rapidly developing area. We focus on studies in which PD is the primary phenotype of analysis but do include some studies that examine PD within the context of broader panicrelated phenotypes. For a simplified overview, the key results from the published genetic association studies with positive findings are summarized in Table 1 . Of note, the level of statistical significance in most of these studies was set at a = 0.05 for a nominal association, but often uncorrected for multiple comparisons. We did not attempt to evaluate the significance of these studies beyond that (as one might with a meta-analysis), given the multiple sources of heterogeneity between the studies. The large amount of available data across the genome allows the presentation of findings systematically by chromosome, a step toward chromosomal mapping of PD. In addition to association analyses, we highlight some of the linkage peaks that have been identified for PD on each chromosome, with two caveats. First, linkage peaks tend not to be well localized, so reported positions of peaks between linkage studies or in relation to candidate genes should be interpreted with caution. Second, despite using a chromosomal presentation to organize the association findings, we do not intend to give the impression that the genes examined are positional candidates; the majority of them are functional candidates, except where noted. We also address novel approaches, such as functional genomics and gene expression studies, which show potential advantages for this field.
Linkage and candidate gene association studies

Chromosome 1
Gelernter et al. 13 (Yale University group) reported suggestive linkage in a set of 20 pedigrees for the 1q43 region at marker D1S2785 (234 cM, LOD score = 2.04), which overlaps a region with an LOD score of 1.1 from a previous genome scan of 23 PD multiplex families conducted by Crowe et al.
14 (University of Iowa group). Some association studies implicated genes on chromosome 1q in susceptibility to PD. For example, Keck et al. 15 have shown that several SNPs in the gene coding arginine vasopressin receptor 1B (AVPR1B), located on the 1q32.1, are nominally associated with PD in population samples of German descent. The involvement of arginine vasopressin in regulation of anxiety behavior was confirmed earlier in both animal models 16 and panic challenge test in healthy subjects. 17 Recently, Koido et al. 18 have shown that the inhibitor of k light polypeptide gene enhancer in B-cells, kinase epsilon (IKBKE) may confer specific susceptibility to PD, and weaker association with MDD. The genetic variations in two regulator of G-protein signaling genes, RGS2 and RGS7, located on 1q31.2 and 1q43, respectively, were associated with PD in a German sample. 19, 20 In addition, the C allele of SNP rs4606 in RGS2 was associated with GAD in an American sample of 607 adults exposed to the 2004 Florida Hurricanes, 21 although it was not associated with PD in a sample of European Americans in a study by Strug et al.
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Chromosome 2
The recent third-pass genome scan from the Columbia University group performed in 120 multiplex PD pedigrees (1591 individuals) provided significant evidence of linkage to region 2q37 at marker D2S125, (261cM, HLOD score = 4.19) using a broad Advances in molecular genetics of PD E Maron et al Advances in molecular genetics of PD E Maron et al Table 1 Continued Abbreviations: ACE, angiotensin I converting enzyme; AG, agoraphobia; ANX, any anxiety disorders; BPD, bipolar disorder; CCK, cholecystokinin; GAD, generalized anxiety disorder; LOD, logarithm of the odds; MDD, major depressive disorder; NA, not applicable; NS, none specified; SAD, social anxiety disorder; SNP, single nucleotide polymorphism; SP, specific phobia.
a Older studies used positional or other designations for polymorphisms. Where available, we added rs numbers from dbSNP.
Advances in molecular genetics of PD E Maron et al PD phenotype under the dominant model. 23 Other regions of suggestive linkage on chromosome 2 were also identified in that analysis. The glutamic acid decarboxylase 1 (GAD1) gene, which produces the GAD67 enzyme responsible for synthesizing GABA from glutamate, located on 2q31.1, was recently shown to be associated with PD and related internalizing phenotypes. 24 The rs8192506 SNP from another gene of interest on chromosome 2q, diazepam-binding inhibitor isoform 1 (DBI), which mediates the feedback regulation of pancreatic secretion and the postprandial release of CCK, showed significant association in a German sample of patients with anxiety disorders characterized by the occurrence of panic attacks. 25 
Chromosome 3
So far there have been no reports of significant linkage to chromosome 3 in PD, although Gelernter et al. 13 showed potential linkage for 3q25.2 region (D3S1279) with agoraphobia (nonparametric linkage score = 2.75, P = 0.005). Analyses of several candidate genes located on 3q showed no association with PD (see Supplementary Table 1) ; however, separate analyses for agoraphobia may be indicated. On the other hand, there is limited evidence for a possible role for two biologically plausible candidate genes on 3p: the genes encoding CCK (3p22.1) and solute carrier family 6 (neurotransmitter transporter, GABA), member 1, SLC6A1 (3p25.3) ( Table 1 ). The involvement of CCK in panic responses is substantiated by challenge studies in patients with PD and healthy subjects, 26 whereas the potential involvement of GABA in PD is supported by benzodiazepine pharmacotherapy as well as several neuroimaging studies showing reduction in cortical GABA levels 27 and brain GABA-A receptor densities 28, 29 in PD patients, although not all studies supported these findings. 30, 31 Among CCK gene polymorphisms, SNP rs754635C/G showed an association with PD in one study, particularly in patients with PD comorbid with MDD. 32 In an earlier study, Kennedy et al. 33 reported no association of SNP rs1799923C/T (À36C > T) with PD, whereas Wang et al. 34 found a weak association of the rs1799923T allele with subjects suffering from panic attacks, but not with the diagnostic phenotype of PD. A study by Hattori et al. 35 failed to find significant association with rs1799923C/T and A(-188)G polymorphisms of the CCK gene, although genotypic and allelic associations with PD were observed for a compound short tandem repeat. Thus, the role of CCK gene variants in predisposition to PD is promising but inconsistent, warranting further study. Five out of 20 SNPs showed nominal associations with PD in a study of the SLC6A1 gene; these did not, however, withstand permutation-based correction for multiple testing. 36 Nevertheless, two of the SNPs in this study showed an increasing strength of association when the patients were stratified according to the severity of panic symptoms, suggesting that the association may be more specifically related to panic attacks.
Chromosome 4
In a follow-on study from the Yale group, Kaabi et al. 37 applied multipoint Haseman-Elston method using a multi-phenotype approach to anxiety disorders that included phenotypic information from PD, social anxiety disorder, and phobias in the set of 19 extended American pedigrees ascertained through probands with PD. Among several locations with significant P-values on this chromosome, the strongest linkage signal was derived from region 4q31-q34 (marker D4S413). In line with these data, Domschke et al. 38 recently studied the genes in neuropeptide Y system in the risk region 4q31, reporting that NPY5R, the gene encoding neuropeptide Y receptor 5, but not NPY1R or NPY2R, may be involved in PD susceptibility. The detected associations appeared to be gender-and phenotype-dependent. Particularly, for two SNPs in NPY5R gene the associations were noted only in females with agoraphobia, but not in groups of females without agoraphobia or males. Earlier animal studies reported increased anxiety-like behavior in rats on administration of NPY Y5 receptor antagonists, 39, 40 supporting the role of the NPY Y5 gene in increased vulnerability to anxiety. There are four published studies of the CCK A receptor (CCKAR) gene, located on the 4p15.2, in PD. Although, some evidence for possible association between CCKAR gene and PD phenotypes was reported in two studies, 32, 41 it was not confirmed by others.
33,42
Chromosome 5 Suggestive linkage with PD on chromosome 5 was reported by Kaabi et al. 37 in the 5q14.2-14.3 region (92.38cM) at marker D5S641 (genome-wide P < 0.01). The candidate most studied on chromosome 5, 5-HT receptor 1A (HTR1A) gene, lies in a different region of this chromosome (5q12.3). Several studies showed suggestive association between rs6295C/G or C(À1019)G, polymorphism of HTR1A, and PD phenotypes. 32, 43 One study also found associations of HTR1A rs6295C/G with panic attacks in other psychiatric disorders, including MDD, bipolar disorder, and schizophrenia, but not in the patients with concurrent PD, probably because of the lower diagnostic reliability in the latter group. 44 However, several other studies did not confirm the association between this polymorphism and PD. 22, 45 Neurobiological analyses provide mixed support for the role of this polymorphism in PD pathophysiology. In one study, a significantly lower activation in several brain regions, including the right ventromedial, orbitofrontal, and anterior cingulate cortices, was found in PD patients homozygous for the G high-risk allele of the HTR1A rs6295C/G polymorphism during processing of anxiety-related facial expressions. 46 Earlier, Lemonde et al. 47 postulated that the rs6295 G allele results in impaired repression of the HTR1A gene, leading to elevated levels of 5-HTR1A autoreceptor and inhibition of the basal raphe neuronal activity. Recently, increased 5-HT1A autoreceptor density was shown in both healthy adults and patients with depression carrying the rs6295 G allele; 48 however, this effect was not observed in another neuroimaging study. 49 Furthermore, patients with symptomatic PD were found to have a significant reduction of 5-HT1A receptors in pre-and various post-synaptic brain regions, 50, 51 whereas patients in remission after antidepressant treatment showed a degree of normalization in post-synaptic 5-HT1A receptor functioning. 51 Thus, the 5-HTR1A receptor and its gene show some evidence of involvement in PD. In addition, a recent pharmacogenetic study showed that HTR1A rs6295G/G genotype was associated with nonresponse to selective 5-HT reuptake inhibitor (SSRI) medications in PD patients. 52 Studies showed that two more genes on chromosome 5q, dopamine type 1 receptor (DRD1), and erythrocyte membrane protein band 4.1 like 4A (EPB41L4A), might be associated with PD.
32,53
Chromosome 6
The available linkage studies provide no data implicating loci on chromosome 6 in PD. Additionally, no associations have been detected between PD and several candidate genes (Supplementary Table 1) , although Politi et al. 54 reported a possible association of rs2736654A/C (Ala111Glu) polymorphism in glyoxalase I (GLO1) gene (6p21.2), but only in the patients without agoraphobia. Importantly, the GLO1 gene has been strongly implicated in the regulation of anxiety-like behavior in mice, suggesting its relevance to pathological anxiety in humans. 55 Nevertheless, the role of this gene in susceptibility to PD was not supported in another association study with a larger number of tested SNPs. 53 
Chromosome 7
Linkage with chromosome 7p15 (maximum LOD score = 2.23 at marker D7S2846, 57.8 cM) was reported by the Iowa group, 14 whereas a re-analysis of these data using a Bayesian approach obtained an 80% probability of linkage to marker D16S749 in that region. 56 Knowles et al. 57 (Columbia University group) reported first-pass genome scan in 23 families from two different generations having at least three affected relatives with PD, revealing a modest linkage with marker MFD20 in the nearby region 7p14.3 (47.1 cM, LOD = 1.71) under a recessive model. Only a few of the studied candidate genes located on chromosome 7 showed significant associations with PD. Particularly, genotypic association was found with the rs324981A/T (Asn107Ile) polymorphism of neuropeptide S receptor 1 gene, NPSR1, (7p14.3) in males with PD derived from a Japanese population. 58 Nominal (but non-significant after Bonferroni correction) associations were also observed in a Spanish PD sample under regressive genetic model for homeobox A1, HOXA1 (7p15.2), and tachykinin, precursor 1, TAC1 (7q21.3) genes. 59 
Chromosome 8
Only suggestive linkage was shown with markers in the 8p23.1 chromosomal region in the Kaabi et al. study. 37 No positive associations were reported by extant candidate gene studies (Supplementary Table 1 ).
Chromosome 9
The results of linkage analyses in a set of 25 families from the Icelandic population with at least one member affected by PD were reported by Thorgeirsson et al. 60 Notably, the authors used an expanded case definition and their data set included patients with PD plus other anxiety disorders. The highest LOD score obtained in their linkage scan was 4.18 in a region on chromosome 9q31 (D9S271, 105.6 cM), corresponding to a genome-wide significance level of P < 0.05. Wang et al. 61 were unable to replicate these results in an isolated population of the Faroe Islands, possibly because of a small sample size. The third-pass genome scan by the Columbia group obtained a maximum LOD score of 3.16 on this chromosome in their recessive model at marker D9S925 (9p22, 32 cM). Several polymorphisms of two genes, delta-aminolevulinic acid dehydratase, ALAD (9q32) and prostaglandin D2 synthase, brain, PTGDS (9q34.3), located near 9q31, were unrelated to PD susceptibility despite the involvement of these genes in the regulation of anxiety-like behavior in inbred mouse strains. 53 
Chromosome 10
Only a study by Smoller et al. 62 in 99 members of one large multiplex pedigree reported linkage to chromosome 10. Their maximum LOD score (2.38) at marker D10S587 (region 10q26) was obtained using a broad anxiety disorder 'diathesis' related to risk for PD. Several genetic association studies have implicated genes on this chromosome in vulnerability to PD. Donner et al. 53 reported that at least 2 of 19 variants in the prosaposin (PSAP) gene in the 10q22.1 region showed a strong allelic association with PD, but not with other anxiety disorders, such as GAD, social anxiety disorder, agoraphobia, or other phobias. PSAP may function as a neurotrophic factor 63 or a neural injury-repair protein; 64 but its specific role in the development of PD requires further analysis. Notably, anxious mice showed increased expression of PSAP in the brain periaqueductal gray (PAG), 55 a region with a putative role in panicogenesis. One small study of the gene encoding cAMP responsive element modulator (CREM, 10p11.21) reported a significant excess of the shorter eight-repeat allele and of genotypes containing the eight-repeat allele in PD patients. 65 The observed associations were limited to PD without agoraphobia and were more pronounced in females. These results were not replicated in their independent Italian and Spanish samples. Moreover, a family-based study showed little evidence of any susceptibility locus for PD either within the CREM gene or in a nearby region on chromosome 10p11. 66 Advances in molecular genetics of PD E Maron et al
Chromosome 11
The Yale group detected a suggestive linkage (LOD = 2.0) on 11p15 at marker CCKBR (5.3 cM) to PD. 13 A number of analyzed candidate genes on chromosome 11 showed no association with PD (Supplementary Table 1 ). However, the CCK brain receptor (CCKBR or CCK2R) gene, a plausible candidate, has shown mixed evidence for association. A CT repeat polymorphism of CCK2R was associated with PD in two case-control studies, 33, 67 but not in a family-based study. 68 Positive associations were also found for two other CCK2R polymorphisms in patients with PD phenotypes. 32, 59 An analysis of the gene for galanin prepropeptide (GAL), located on 11p13.3, showed no associations of this gene with PD in subjects from both sexes, but found an association with severity of PD symptoms in females that remained significant after correction for multiple testing. 69 Another gender-dependent finding was reported for progesterone receptor (PGR) gene (11q22.1), showing strong allelic association with the G331A polymorphism in females, but not in male patients. 70 
Chromosome 12
The study by Smoller et al. 62 provided evidence of linkage for PD with or without agoraphobia on chromosomal region 12q13 at marker D12S368 (nonparametric linkage score = 4.96, P = 0.006). A suggestive linkage on 12q was also identified in the Columbia third-pass scan at marker PAH (109 cM, HOMLOD = 1.71). 23 Several genes within this or nearby chromosomal regions were included in association studies, with some of them showing positive results. One study reported a nominal association with the gene for purinergic receptor P2X, ligand-gated ion channel, 4 (P2RX4) in a German sample of patients with anxiety disorders, mostly with PD. 71 The newly identified isoform 2 of the TPH gene (TPH2) in 12q21.1 region is preferentially expressed in neuronal tissue and has functional polymorphisms involved in the regulation of brain 5-HT synthesis, making this gene a promising candidate. 72 However, a recent association study by Mö ssner et al. 73 did not find any associations between two common SNPs, rs4570625 and rs4565946, located in the putative transcriptional control region and in intron 2 of TPH2, respectively, and PD in a sample of German descent. A possible association with the rs4570625 SNP was observed in a Korean sample of PD patients, 74 where a significantly lower frequency of T allele was detected in total sample and in females, but not in male subjects. Another study found no significant associations with TPH2 gene SNPs rs1386494 and rs1386483 in patients with PD; however, an association with rs1386494 was observed in a subgroup of females with pure PD phenotype, indicating possible gender-specific effect of TPH2 gene variants in PD. 75 
Chromosome 13
In a linkage analysis of a broad PD syndrome (PD combined with bladder problems, severe headaches, mitral valve prolapse, and thyroid conditions), performed in 60 multiplex pedigrees, the Columbia group found a significant linkage on chromosome 13q (D13S793, 76 cM), under a dominant genetic model with the highest LOD score of 3.57. 76 Earlier linkage analyses revealed a strong peak on the chromosome 13q at marker D13S779 (96 cM, LOD score 4.2) among the families with the mentioned medical conditions, suggesting that they may represent a group of 'chromosome 13 syndromes,' which includes PD. 77 This hypothesis was clinically confirmed and extended by Talati et al., 78 who showed that probands with PD as well as their first degree relatives were more likely to have symptoms of chromosome 13-associated syndromes.
Two genes on the chromosome 13q region, D-amino acid oxidase activator (DAOA/G30) LG30 in region 13q33.2 and serotonin receptor 2A, (HTR2A) in 13q14.2, showed possible relation to PD-related phenotypes. Although several polymorphisms within DAOA/G30 gene showed associations with PD, 79 this locus has also been linked to mood disorders, neuroticism, and schizophrenia. [80] [81] [82] These results strengthen the notion of a genetic overlap between related phenotypes, commonly considered as distinct entities. Significant associations were detected between HTR2A silent rs6313T/C (T102C) polymorphism and pure, but not comorbid, PD phenotypes in both Japanese 83 and Estonian samples. 32 However, these findings were not confirmed by studies in German, Canadian, or Korean samples, possibly because of the ethnic and phenotype variations. [84] [85] [86] [87] Although there is no salient evidence for the role of 5-HT2A receptors in PD, some animal studies had shown that stimulation of 5-HTR2A receptors of dorsal and ventrolateral PAG caused panicolyticand anxiolytic-like effects, respectively.
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Chromosome 14
A recent linkage analysis conducted in 1602 twins and siblings, selected from a Dutch population-based twin-family sample, revealed a strong linkage signal (LOD score 3.4, empirical P-value 0.07) at chromosome 14 for marker D14S65 to Spielberger's Trait Anxiety. 10 This finding is in line with the data of Kaabi et al. 37 reporting a significant linkage for the same region at chromosome 14q23, as well as with a linkage evidence for two anxiety phenotypes, including PD and simple phobia. 13, 90 Intriguingly, a strong association with PD phenotype was recently detected for rs945032 SNP of bradykinin receptor B2 gene (BDKRB2), which lies in the nearby 14q32.2 region, supporting a role for 14q locus in susceptibility to PD. 59 BDKRB2 gene product is involved in the mechanisms of vasodilation, edema, inflammation, blood vessel permeability, and also protects against hypoxia/reoxygenation-induced neuronal cell apoptosis. 91 Notably, the above-mentioned polymorphism of BDKRB2 gene was also associated with substance abuse and bipolar disorder. 59 
Chromosome 15
In the Columbia group's third-pass genome scan, Fyer et al. 23 reported significant linkage to the centromeric region on 15q (near GABA-A receptor subunit genes). Their maximum nonparametric linkage-LOD score of 2.56 occurred at 12 cM for broad panic phenotype that included sporadic and limited symptom panic attacks in addition to PD. Earlier, Gratacò s et al. 92 identified a duplication of human chromosome 15q24-26, DUP25, which was significantly associated with panic/agoraphobia/social phobia and joint laxity in families as well as with PD in non-familial cases. However, no evidence for the role of DUP25 in anxiety disorders was found in consequent studies. [93] [94] [95] Furthermore, only one out of four novel polymorphisms examined in the gene for neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), located in the duplicated region of DUP25, showed a nominal association with PD phenotype. 96 
Chromosome 16
No linkage was reported for PD with chromosome 16, however 16q region was linked to social phobia by the Yale group in 17 American pedigrees (163 subjects) ascertained through probands with PD (LOD = 2.22; P = 0.0003). 97 To date, the findings from association studies do not support a major role of chromosome 16 gene variants in the vulnerability to PD (Supplementary Table 1 ).
Chromosome 17
No substantial linkage has been reported between PD and chromosome 17. Notably, the serotonin transporter (5-HTT) gene, SLC6A4, probably the most studied candidate gene in psychiatry, is located on 17q11.2. Only one 98 of several case-control association studies in different ethnic groups reported association of PD with the functional length polymorphism in the 5 0 regulatory promoter region (5-HTTLPR) (Supplementary Table 1 ). A recent meta-analysis, which included data from 10 case (n = 2050)-control (n = 3136) studies (OR = 0.91, P = 0.14), concluded that 5-HTTLPR is not associated with PD. 99 An Italian study reported that the high-expressive L variant of 5-HTTLPR was associated with a better response to 12-week treatment with an SSRI paroxetine in female patients with PD, 100 but this finding was not replicated in a Korean PD sample. 101 Recently, Strug et al. 22 showed strong and consistent association across several SNPs in the SLC6A4 gene and PD phenotype, the most significant association being at rs140701. However, these results may have been confounded by a significant gender disproportion between studied groups, in which more females were included in PD sample compared to controls (see Table 1 ).
Keck et al. 15 detected nominally significant associations with several SNPs in the corticotropin releasing hormone receptor 1 (CRHR1) gene in region 17q21. 31 and PD, with the strongest association for rs242937 in both initial and replication samples. The involvement of CRHR1 in anxiety regulation is supported by the evidence from animal experiments, where the mice lacking these receptors in limbic regions showed reduced anxiety-related behavior. 102 Several studies have implicated the angiotensin I converting enzyme 1 (ACE) gene, localized on 17q23.3, in the predisposition to PD. ACE catalyzes the conversion of angiotensin I to the far more potent vasoconstrictor angiotensin II. On the basis of studies with angiotensin II type-2 receptor knock-out mice and an animal model of lactate-induced panic-like responses, angiotensin II has been suggested as a contributor to the pathogenesis of panic attacks. 103, 104 Studies in Sweden and German samples revealed significant malespecific associations with the I (insertion) allele of I/D functional polymorphism. 105, 106 Furthermore, Erhardt et al. 107 have identified an association of two SNPs (rs4311 and rs4333) in the ACE gene with syndromal panic attacks. No association with ACE polymorphism was found in a study of Japanese patients with PD. 108 
Chromosome 18
There is no evidence supporting linkage between chromosome 18 and PD, except the study of MacKinnon et al., 109 reporting linkage over five consecutive 18q marker loci, with a maximum z-score of 4.7 at D18S61, in families ascertained through probands with bipolar I disorder and comorbid PD. Two of six analyzed SNPs in the gastrin-releasing peptide (GRP) gene, 18q21.32, showed nominally significant associations with broad and intermediate PD phenotypes in a Columbia group study. 110 
Chromosome 19
No linkage data supporting the role of chromosome 19 in genetic transmission of PD have been reported to date. Furthermore, no significant associations with PD were observed for some analyzed candidate genes (Supplementary Table 1 ), except for a nominal association with the glutamate receptor, ionotropic, kainate 5 (GRIK5), located in the region 19q13.2.
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Chromosome 20
There is no evidence supporting linkage between chromosome 20 and PD. Strong association with PD phenotype was recently detected under log-additive model by Gratacò s et al. 59 for growth hormone releasing hormone (GHRH) gene, located on 20q11.23 region, which is in line with the evidence of growth hormone dysfunction in panic patients.
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Chromosome 21
No evidence for linkage of chromosome 21 with PD has been reported to date. Among the genes studied on chromosome 21, only the gene for ATP-binding cassette, sub-family G (WHITE), member 1 (ABCG1), Advances in molecular genetics of PD E Maron et al showed a male-specific association with PD and MDD phenotypes in a small Japanese sample. 113 
Chromosome 22
A maximum LOD score of 4.11 was reported by the Columbia group between chromosomal location 22q12-13 (D22S445, 46 cM) and their broad 'PD syndrome' under a dominant genetic model. 76 Several biologically plausible candidate genes located on 22q showed promising associations with PD. The observation of an anxiogenic effect of caffeine administration 114, 115 has implicated adenosine, and particularly the adenosine A2a receptor (ADORA2A), located at 22q11.23. Deckert et al. 116 were first to show that a silent coding polymorphism rs5751876C/T (C1976T) in exon 2 of the ADORA2A gene was associated with PD in a German sample. This finding was partially replicated by Hamilton et al., 117 who provided evidence for linkage between the ADORA2A locus and PD in the Columbia group Caucasian PD sample. This association was not seen in Japanese 118 or Chinese 119 samples. The fact that a positive association was found in the Western, but not in Asian populations, suggests that the relationship may be specific to ethnicity.
The catechol-O-methyltransferase gene (COMT), which codes for a major methylation enzyme metabolizing the monoamine neurotransmitters, including dopamine, has emerged as a promising candidate gene in the pathogenesis of PD. The COMT gene maps to chromosome 22q11.21, and is expressed as a larger membrane-bound protein or a smaller soluble form. Both forms include a functional polymorphism rs4680G/A (Val158Met), wherein the valine allele shows a significantly higher COMT activity relative to the methionine allele. This functional variant in the coding sequence of COMT gene has attracted a number of studies in various PD-related phenotypes (see Table 1 ). 22, [120] [121] [122] [123] [124] [125] [126] [127] A recent meta-analysis of six available case-control studies showed significant association of the COMT 158 Val allele with PD in the Caucasian samples and, conversely, a trend toward association of the COMT 158 Met allele with PD in the Asian samples. 128 Interestingly, stratification for gender as well as ethnicity revealed that the associations of the 158 Val allele in Caucasians and, reciprocally, the 158 Met allele in Asians were restricted to females. Furthermore, a recent fMRI study indicated an increased activation in the right amygdala in patients with PD carrying at least one COMT Val allele in response to fearful faces. 129 Finally, the gene for translocator protein (TSPO), known also as the peripheral benzodiazepine receptor, located on the 22q13.2, showed possible association with PD in a Japanese sample. 130 Chromosome X Only weak LOD scores between 1 and 2 were observed on chromosomes X in earlier linkage studies. 57, 60 The transcriptionally more active longer alleles and genotypes of a functional polymorphism of the monoamine oxidase A (MAOA) gene, uVNTR, located on Xp11.3, showed a significant association with PD in females, but not in male patients. 131 Similar gender-dependent associations with longer allele genotypes were observed in female patients with PD 98 and panic attack phenotype 125 in other studies. These studies suggest a role for MAOA promoter region polymorphism in vulnerability to PD in females; however, this gender effect was not supported by a family-based study. 132 
Interpretation of linkage and candidate gene studies
The linkage and candidate gene association studies have so far showed only weak success to identify reliable and replicated evidence for the genetic substrate of PD. The most promising findings of linkage scans, with some support from association studies, suggest that chromosomal regions 13q, [76] [77] [78] 14q, 10, 37 4q31-q34, 37 22q, 76 and probably 9q31 60 may be relevant to PD susceptibility and require further analysis. Only few candidate genes, such as NPY, DAOA/G30, ADORA2A, and COMT, were chosen for association analysis primarily because of being under a linkage peak. The published candidate gene studies in PD have provided inconclusive results even for the genes with a strong a priori rationale for analysis. The genetic research to date has been mostly restricted to small phenotypically and ethnically diverse data sets with genotyping of limited numbers of SNPs. Failure to identify or replicate previously detected susceptibility loci and genetic variations in PD, as well as in other psychiatric disorders, has caused skepticism regarding the perspectives of genetic research in psychiatry. However, several aspects of genetic studies in PD, including sample characteristics and selection of gene candidates, need to be taken into account while interpreting the significance and possible impact of their results. All available PD association studies are frankly underpowered, with only a few of them including samples larger than 200 patients, raising the risks of both, false positive and false negative findings. 11 The overrepresentation of females in PD samples, particularly in the studies conducted in Caucasian populations, does not allow to draw conclusions for both genders, especially when sex-specific effects are suspected. Possible bias might also be caused by gender disproportion seen in some studies, in which control groups contained a smaller number of females as compared to the patients (see Table 1 ).
Three common strategies have commonly been applied in selection of candidate genes for examination of association with PD phenotypes. The first strategy is built on a strong rationale of established clinical and neurobiological findings in PD, such as the therapeutic effect of SSRIs, effect of CCK and adenosine in panic challenge, and alterations in brain GABA and 5-HT systems. Nevertheless, there are high clinical and neurobiological variations between PD patients. Not all of them respond similarly to the same medications, whereas the neurobiological alterations and panic sensitivity largely vary between patients. These 'individual factors' are often ignored or not adequately assessed in the association studies. This may be a reason for equivocal results obtained in 'whole sample' analyses and could explain why, despite evidence-based selection of candidate genes, the findings remain inconclusive. Furthermore, differences in the frequency of risk alleles between PD and control groups are usually within a range of 10%, suggesting that genetic variants may have moderate but hardly decisive contribution to PD susceptibility. The lack of clear relationship between genetic and neurobiological markers of disease confuses the interpretation of genetic findings in PD. An improved understanding of neurobiological pathways of PD could contribute to a more effective identification of candidate genes. The second strategy is based on the results of animal studies, exploring the genes that regulate anxiety-like behavior. Given the survival value of the evolutionary-conserved panic response, this cross-species approach has great potential for the identification of candidate genes for anxiety disorders. 53 However, the correlations between human anxiety and panic phenotypes and those in animal models are far from straightforward. The third strategy is selecting genes on the basis of existing findings in other psychiatric disorders. This approach has some advantages, considering high comorbidity between PD and other psychiatric conditions and the evidence of partial overlap in genetic susceptibility between PD and other internalizing disorders. 4, 9 However, negative findings could be expected for specific genes involved in different conditions. Notably, positive associations detected for several genetic polymorphisms in PD were also found in schizophrenia, 133 depressive disorders, 18, 24, 113, 134 bipolar disorder, 59, 135 and other anxiety disorders, or anxiety-related personality traits. 21, 24, 86, 127 Accordingly, linkage studies have shown a chromosomal overlap between PD and other anxiety phenotypes, 10 MDD, 136 and bipolar disorder. 137 This may indicate that some genetic variants confer a general susceptibility to several syndromes or personality traits, rather than a specific susceptibility to any particular disorder.
At least 46 candidate genes were implicated by association studies in vulnerability to PD (Table 1) . In a realistic simulation of a typical genotyping approach for a commonly studied candidate gene, using 10 SNPs in the COMT gene, as an example, Sullivan 138 recently showed that such studies are very likely to produce one or more significant but false positive findings. In fact, most of the positive findings in PD are just nominal, not withstanding correction for multiple testing and/or not replicated. The incorporation of some of these genes into PD pathogenesis is rather speculative and not yet based on neurobiological or clinical findings. In addition, the detection of a true association demands not only that the gene product should be involved in pathways relevant to the development of the trait or disease of interest, but also that the gene contains variants capable of influencing its regulation or function. 139 Furthermore, there is an increasing evidence that interaction between genetic and epigenetic regulation may clarify inherited and acquired predictors of the risk for psychiatric disorders. 140 Particularly, epigenetic mechanisms involving allele-specific DNA methylation, and thus influencing regulation of gene expression, were recently shown for the HTR2A rs6313T/C 141 and COMT Val158Met polymorphisms, 142 both showing significant association with several psychiatric disorders, including PD. More insight into the manner in which DNA sequence interacts with epigenetic modifications may show how inherited information is translated into pathological phenotypes. 140 Still, inter-individual variability in the details of such translation could explain the frequent inconsistencies in the results produced by genetic association studies of PD.
Genome-wide association studies
Rapid progress in genomic research and bioinformatics promises to provide the means for far more comprehensive and powerful studies in PD. Recently, genome-wide association (GWA) methods were applied to analyze the genetic substrates of several psychiatric disorders and related traits, including schizophrenia, [143] [144] [145] [146] bipolar disorder, [147] [148] [149] [150] major depression, 151, 152 neuroticism, 153, 154 and antipsychotic treatment response. 155, 156 Notably, these psychiatric GWA studies have detected new risk markers that were not earlier identified in candidate gene association studies, whereas none of the previously described markers were replicated or confirmed by whole genome screening. 157 To date, no GWA study has been performed in an adequately powered sample of patients with PD. Otowa et al. 158 recently conducted GWA screening in 200 Japanese PD patients and the same number of matched controls, which showed significant associations with seven SNPs located in or adjacent to the genes plakophilin 1 (PKP1), pleckstrin homology domain containing, family G member 1 (PLEKHG1), transmembrane protein 16B (TMEM16B), calcium binding and coiled-coil domain 1 (CALCOCO1), sidekick homolog 2 (SDK2), clusterin (CLU), and one unknown gene. Among detected SNPs, rs9302001, located on 13q32, is within the area of PD 1 (PAND1), which was linked to PD. 76 Additionally, they reported 42 SNPs that may have potential role in susceptibility to PD, none of which overlapped with genetic markers associated in earlier candidate gene studies. Considering the small sample size of this study and number of markers tested, the results should be taken with caution and require replication in larger GWA studies. Several international research groups are now collaborating to analyze the genetic substrates of PD. For example, the recently formed Panic International Consortium (PAN Á I Á C) is aiming to replicate earlier findings on genetic associations and to identify new markers using the largest combined and, therefore most powered sample of patients to date. The results of this joint effort are likely to shed more light on the genetic underpinnings of PD in the near future.
Novel conceptual and analytic approaches, such as pathways-based analyses, may help to advance GWA studies in psychiatric disorders. Recently, these analytic tools had implicated ion channel structural and regulatory genes in susceptibility to bipolar disorder. 159 Other promising strategies combining brain imaging as a quantitative trait and genetic data from GWA studies had identified some unanticipated risk genes for the development of schizophrenia. 160, 161 These approaches provide new perspectives for GWA studies in psychiatric genetics and may prove advantageous for further inquiry into PD genetics.
Challenge tests validation
Laboratory panic challenge models may provide clues to genetic predisposition to PD. At least one-third of control subjects with no psychiatric disorder show a panic-like response to challenge agents, suggesting endophenotypic markers for vulnerability to panic behavior. To date, only a few studies had explored the associations between genetic polymorphisms and a susceptibility to induced panic. One of them has implicated two polymorphisms of ADORA2A gene, rs5751876C/T and C2592Tins, in self-reported anxiety induced by caffeine administration in 94 healthy subjects. 162 The carriers of rs5751876 T/T and the C2592 Tins/Tins genotypes reported greater anxiogenic responses to the acute dose of caffeine, thus confirming previously noted associations between ADORA2A gene and PD. Schmidt et al. 163 have reported that subjects homozygous for the L variant of 5-HTTLPR were at a greater risk for behavioral hyper-reactivity to 35% carbon dioxide (CO 2 ) challenge than those with S-allele genotypes. On the contrary, in another study of patients with PD, CO 2 reactivity was not influenced by 5-HTTLPR genetic variants. 164 Initial findings on the associations between 5-HTTLPR, MAO-A uVNTR, and panic responses to CCK-4 challenge test in a small sample (n = 32) 165 were not confirmed in a consequent larger sample (n = 110) of healthy subjects. 166 In the latter study, only one of the nine gene candidates previously implicated in PD showed effects on the susceptibility to CCK-4 challenge. Specifically, the TPH2 gene SNP rs1386494 was associated with panic attacks rates in healthy females, 166 supporting a previous finding of an association between this polymorphism and PD in female patients. 75 The predictive value of genetic association profiling with challenge tests in healthy subjects, however, is unclear. Plausibly, a multifaceted clinical phenotype like PD may have more complex genetic basis than pure panic condition induced by challenge test. Perhaps not all genetic associations showed in studies with PD patients could be validated or confirmed by challenge tests in healthy subjects. Furthermore, most of challenge tests are conducted in young individuals who may or may not experience panic attacks or develop PD or another anxiety or mood disorder in the future. Nevertheless, the challenge tests have potential to increase our knowledge about the endophenotypic nature of panicogenesis and PD.
Gene expression studies
Analyses of peripheral gene expression markers in PD may provide further insight into genetic substrates of PD. Microarray studies of peripheral gene transcription signatures have suggested a shared expression of the majority of genes in brain and peripheral blood 167 and have differentiated between patients with posttraumatic stress disorder and healthy subjects. 168, 169 Recently, Philibert et al. 170 reported that transcriptional signatures of lymphoblast cell line derived from patients with PD (n = 16) were significantly different from the transcripts in subjects without psychiatric history (n = 17). Specifically, the expression of 2469 transcripts was increased and expression of 354 transcripts was decreased in patients as compared to healthy subjects. To further analyze the transcriptional signatures associated with panicogenesis, Maron et al. 171 applied the Illumina microarray platform for whole genome expression profiling in healthy subjects participating in the CCK-4 challenge test. In the first stage, at least 61 genes were found to be differentially expressed between the CCK-4 panickers (n = 18) and non-panickers (n = 13), a substantial fraction of which belonged to the mRNA transcripts of interferon gene group or to genes involved in immune response, whereas others were related to clinical phenotypes of asthma (PHF11), diabetes (OAS1), and coronary artery disease (CCL2). Notably, all these medical conditions are associated with the occurrence of panic attacks. In the second stage of this study, the transcriptional levels of 226 genes showed changes 2 h after CCK-4 challenge. Most of these transcripts could be grouped as related to immune, enzymatic, or stress regulation systems. Such a broad physiological response seems plausible considering the acute and stressful nature of panic attacks. Importantly, both this 171 and Philibert et al.
170
studies detected changes in the expression level of sterol regulatory element-binding transcription factor 2 (SREBF2) gene, which is located on the chromosome region 22q13 and is known to regulate cholesterol homeostasis. Alterations in cholesterol levels have been implicated in both PD and pentagastrin-induced panic attacks, [172] [173] [174] suggesting that SREBF2 gene could be a target for association studies in PD. Interestingly, some markers of SREBF2 gene were associated with schizophrenia in a German as well as in a Scandinavian sample, 175 whereas somatostatin receptor 3 (SSTR3) gene, which is also located on the 22q13 region, recently showed at least nominal association with PD. 59 Taken together, the analysis of peripheral gene expression may extend our knowledge of the genetic basis underlying panic phenomenology and point to the biological proximity between panicogenesis and several medical conditions, which may be important in the search for new research and treatment targets.
Clinical and molecular integration
The understanding of genetic underpinnings of PD will not be of full value without a conceptual integration of the clinical phenomena of PD with psychological models and neurobiological or molecular substrates underlying its development and course ( Figure 1 ). Panic symptoms are not specific for PD; they may be observed under normal or physiologically challenging conditions and can be induced by substance use or occur in some medical conditions. Panic symptoms may mimic certain cardiac, respiratory, neurological, or metabolic symptoms, which in their own turn are associated with an increased risk of panic attacks. The co-occurrence of PD with medical conditions with elevated risk of panic attacks 176, 177 may indicate that panic vulnerability shares pathogenetic mechanisms and genetic origins with these conditions. The possibility of connections between medical conditions and panicogenesis has been preliminarily supported by genetic findings 59, 171 and other evidence of shared alterations in PD and cardiovascular or respiratory pathologies. [178] [179] [180] [181] [182] For example, b-2-adrenoreceptors are implicated in pathogenesis and treatment of asthma as well as in the normalization of receptor affinity after treatment with antidepressants in patients with PD, whereas a downregulation of their mRNA transcripts was observed after CCK-4-induced panic in healthy subjects. 171, 179 Notably, the polymorphisms of b-2-adrenoreceptor gene may contribute to risk and therapeutic response of asthma, however, these data are controversial 183, 184 and no genetic association was detected for PD diagnosis. 59 Supposedly, the down-or upregulation of certain genes could be responsible for manifestation and severity of corresponding panic symptoms. The fact that patients with PD vary in respect to predominant panic symptomatology (respiratory, cardiac, digestive, cognitive, or mixed) may also support the notion that particular genes and molecular pathways are responsible for the respective clinical phenotypes. However, the specific knowledge to support these hypotheses is lacking. In this context, the example of b-2-adrenoreceptors is noteworthy, but still superficial. The epigenetic regulation, expression level, electrophysiological properties, and functional role of these receptors may be different in PD, medical diseases, that is asthma, and physiological responses.
Although the onset of first panic attack is usually unexpected, it has been commonly assumed that this manifestation stems from long-standing pathogenetic processes. According to cognitive models, panic attacks are triggered by catastrophic misinterpretation of bodily sensations, 5 false alarm because of increased arousal and self-focused attention, 6 abnormal anxiety sensitivity, 185 or discomfort intolerance. 186 Klein's integrative concept of 'false suffocation alarm' 7 postulates that PD patients have a low stimulation threshold of the asphisiostat, a physiological mechanism of protection from potentially lethal stimuli. These models have been successfully applied in cognitive and behavioral therapies of PD. However, they explain more the psychological components of panic attacks and associated clinical features, such as anticipatory anxiety and agoraphobia, than the onset and paroxysmal nature of PD, which is more likely to be elucidated by biological mechanisms. To this point, some, but not all, clinical trials have shown that pharmacological treatment may provide faster and more robust reduction in the frequency of panic attacks than cognitive therapy. [187] [188] [189] Neurobiological models have proposed that panic attacks are caused by a spontaneous neuronal discharge in the brainstem structures, 190 particularly in the dorsal PAG, 191 which is likely to occur if neurochemical-physiological balance controlling panic-like responses is impaired. Importantly, neuroendocrinological studies showed that neither panic attack nor electrical stimulation of the PAG activated hypothalamic-pituitary-adrenal axis, which has however been related to anticipatory anxiety. 192 The activation in the dorsal PAG and/or PAG-linked pathways may be responsible for the feelings of terror or extreme discomfort, which are the key qualities of a panic attack. Although the PAG is a candidate for the primary site of panic response, 191, 193 the neuroanatomical circuits of PD include the prefrontal cortex, the insula, the thalamus, the amygdala, the locus ceruleus, the hypothalamus, and the solitary and the parabrachial nuclei. 8, 190 The central nucleus of the amygdala stands at the core of autonomic, behavioral, and neuroendocrine components of a panic attack. 8 It should be noted that a panic reaction to external or internal cues perceived as life-threatening is a normal physiological survival reflex.
194 This is also supported by the findings of increased susceptibility to panic challenge in up to 50% of non-psychiatric subjects, although only 3-5% of general population develop PD. This dramatic difference between evolutionary predisposition and actual prevalence of PD may indicate that PD develops when the activity and/or expression level of certain genes linked to neurobiological, physiological, or cognitive substrates relevant to panic are shifted and persist in a pathological range. Taken into account the clinical phenomenology and pathogenetic complexity of PD, one may suggest that these genes could belong to different functional clusters (Figure 2 ).
Summary and further recommendations
Taken together, the genes involved in susceptibility and development of PD are still undiscovered or not fully understood. Considering findings and limitations of currently available association studies in PD, we can draw two conclusions: first, the genes for which a major role in PD has been 'excluded,' in fact are not ultimately irrelevant; and second, the genes with preliminary evidence for a role in PD still require more proof of their involvement. To date, only the association of COMT Val158Met polymorphism and PD has been shown in several studies in independent samples and also confirmed by a metaanalysis. However, this association may be moderated by gender and ethnicity and is not exclusive to PD, being also reported for other internalizing phenotypes, 127 cognitive functioning, 195 neuronal emotional processing, 129 dorsolateral prefrontal and hippocampal volume, 196 alexithymia, 197 and other psychiatric disorders, such as schizophrenia and bipolar disorder. 198 PD might exist in many distinct genetic forms, each with a different set of genes, but also in one form with certain genes reflecting broader vulnerability to panicogenesis. 3 There are some evidences that several genetic variations may be differentially associated with pure or comorbid PD phenotypes or PD with and without agoraphobia. However, the heterogeneity in PD phenotypes, age of onset, subtypes and severity of panic attacks, and familial aggregation was not sufficiently accounted for in most of published studies and should be more carefully addressed in further analyses. Although clinical practice does not provide evidence that panic severity or phenotypes differ between male and female patients, the higher prevalence of PD in females and some association findings indicate necessity of gender-specific genetic analyses. Additionally, in contrast to genetic research in MDD, the gene-environment interactions in PD have not yet been explored and should be addressed in further studies. Other comprehensive genetic approaches, including GWA, the analysis of copy number variants, 199 and the study of regulatory small non-coding RNAs, 200 may lead to uncovering new genomic mechanisms of PD. The genetic basis of PD and panicogenesis may be not only related to DNA sequence, but also to translational changes. Different scenarios in gene expression activity could potentially be predicted by certain genetic variations, particularly by those closely linked to epigenetic regulation. The detection of such polymorphisms requires combined analysis of stable genetic information and changes on the transcriptional levels. Furthermore, the initial efforts to incorporate epigenetic approaches into analysis of complex diseases 140 indicate a high potential of these methods in advancing the research on PD pathogenesis. Despite the increasing complexity of research approaches, the evolutionarily conserved nature of panic phenomena and distinctive clinical profile position PD as one of the most promising psychiatric conditions for genetic research. The molecular genetics of PD remains a stimulating and challenging area of discovery.
